Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
Fiche du document
2015
- doi: 10.4414/smw.2015.14100
- issn: 0036-7672
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.4414/smw.2015.14100
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/25999239
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1424-3997
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_0B8C497CD9720
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
TherapyCiter ce document
P. Samaras et al., « Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland », Serveur académique Lausannois, ID : 10.4414/smw.2015.14100
Métriques
Partage / Export
Résumé
The availability of drugs such as thalidomide, bortezomib and lenalidomide changed the landscape in myeloma treatment and has extended the median survival up to 10 years with a substantial improvement in quality of life. This development prompted a Swiss expert panel to re-evaluate the current status and formulate updated clinical recommendations for the diagnosis and treatment of plasma cell myeloma. These recommendations should help clinicians in their decision making to achieve the best outcome based on currently available data.